Genome wide association study of apparent treatment resistant hypertension in the CHARGE consortium: The CHARGE Pharmacogenetics Working Group

Keyphrases

• Pharmacogenetics 100%
• Genome-wide Association Study 100%
• Resistant Hypertension 100%
• CHARGE Consortium 100%
• European Ancestry 80%
• African Ancestry 80%
• Medication Classes 60%
• Hypertension 40%
• Systolic Blood Pressure 40%
• Diastolic Blood Pressure 40%
• Single nucleotide Polymorphism 40%
• Blood Pressure 40%
• Antihypertensive Therapy 40%
• CASZ1 40%
• Blood Pressure Control 20%
• Odds Ratio 20%
• Meta-analysis 20%
• Logistic Regression 20%
• Hypertension Risk 20%
• Combined Analysis 20%
• Risk Loci 20%
• Fixed Effects 20%
• Control Status 20%
• Sex Studies 20%
• Program Research 20%
• Phenotypic Drug Discovery 20%
• Million Veteran Program 20%
• 95% Confidence Interval 20%
• Separate Analysis 20%
• Inverse Variance Weighted 20%
• Case-control Genome-wide Association Study 20%

Medicine and Dentistry

• Genome Wide Association Study 100%
• Pharmacogenetics 100%
• Resistant Hypertension 100%
• Blood Pressure 60%
• Diastolic Blood Pressure 40%
• Systolic Blood Pressure 40%
• Antihypertensive Agent 40%
• Single Nucleotide Polymorphism 40%
• Genetics 40%
• Hypertension 40%
• Logistic Regression Analysis 20%
• Meta-Analysis 20%
• Pressure Control 20%
• Odds Ratio 20%

Biochemistry, Genetics and Molecular Biology

• Pharmacogenetics 100%
• Blood Pressure 100%
• Genome-Wide Association Study 100%
• Diastolic Blood Pressure 66%
• Systolic Blood Pressure 66%
• Single-Nucleotide Polymorphism 66%
• Genetics 33%
• Genomics 33%